Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes mellitus~* Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day alone for at least 10 weeks prior to screening must be \>=7.0% and \<=10.0% at screening~* Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day and one of oral antidiabetic drug (OAD) for at least 10 weeks prior to Visit 1 must be \>=7.0% and \<=9.0% at screening and \>=7.0% and \<=10.0% at placebo run-in~* Male and female patients on diet and exercise regimen who are pre-treated with OAD alone for at least 10 weeks prior to Visit 1 must be \>=7.0% and \<=10.0% at both screening and placebo run-in~* Age at informed consent must be \>=20 years~* BMI at screening must be \<=40 kg/m2~* Further inclusion criteria apply~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose values \>270 mg/dL (\>15.0 mmol/L) after an overnight fast during switch/washout/placebo run-in period and confirmed by a second measurement~* Patients who are drug-naïve at screening visit or treat with any of insulin, thiazolidine dione, sodium-glucose co-transporter 2 (SGLT-2) inhibitor within 10 weeks prior to informed consent.~* Acute coronary syndrome, stroke or transient ischemic attack within 12 weeks prior to informed consent~* Indication of liver disease, defined by serum levels of either alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal as determined during screening and/or switch/washout/placebo run-in period~* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m2 (Japanese equation) as determined during screening and/or switch/washout/placebo run-in period~* Further exclusion criteria apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- empagliflozin 10 mg (Type: EXPERIMENTAL): empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
- empagliflozin 25 mg (Type: EXPERIMENTAL): empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).